Learned intermediary doctrine answers a single question in products liability: to whom must the warning run? For most consumer goods the answer is the person who will use them. For prescription drugs and devices the answer is the prescribing physician, who evaluates the individual patient and decides whether the benefit outweighs the risk.
The doctrine is often described as a shield for manufacturers, which understates what it actually does. It redirects the duty rather than removing it. A warning that understates the gravity of a risk, buries it or fails to reflect newer data is still actionable, and California has its own framework for prescription product claims that sits alongside the rule. This guide covers the scope, the adequacy test, the causation hurdle and the recognised exceptions.
The rule and its rationale
A physician is a trained professional who assesses the individual patient, weighs alternatives and makes a prescribing decision. Placing the warning obligation there reflects how the decision is actually made and avoids the futility of expecting a manufacturer to communicate individualised risk to patients it will never meet. An adequate warning to the prescriber discharges the duty.
The rule applies to prescription products only. Over the counter medicines and ordinary consumer goods fall outside it, because no professional intermediary exercises judgement between the manufacturer and the user.
What makes a warning adequate
Adequacy is not satisfied by mentioning that a risk exists. The warning must convey the nature and the gravity of the risk in terms that allow the prescriber to weigh it. A serious risk buried among dozens of trivial ones, or described in language that minimises it, can be inadequate even though it is technically present.
The obligation is also continuing. Information emerging after a product reaches the market can require the warning to be updated, and a failure to act on post marketing data is one of the most common routes to liability under this doctrine.
The causation hurdle
An inadequate warning is not enough on its own. The claimant must generally show that a better warning would have changed the prescribing decision. Where the treating physician testifies that the same prescription would have been written regardless, the deficiency did not cause the injury and the claim fails however poor the warning was.
That requirement makes prescriber testimony the pivot of most cases, and it explains why claims are often built around what the physician says they would have done had the risk been stated accurately.
| Product type | Who must be warned | Basis | Practical effect |
|---|---|---|---|
| Prescription drug | Prescribing physician | Professional judgement intervenes | Adequacy judged from the prescriber view |
| Prescription device | Implanting or prescribing clinician | Same reasoning | Clinical literature matters |
| Over the counter medicine | The consumer | No intermediary | Label must warn the user |
| Directly advertised drug | Physician and patient | Manufacturer entered the decision | Shield pierced in some jurisdictions |
When the shield is pierced
- Direct to consumer advertising — a manufacturer that markets straight to patients has inserted itself into the decision.
- Mass immunisation programmes — no individualised prescribing relationship exists.
- Contraceptives — several jurisdictions require patient directed warnings.
- Emergency settings — no considered prescribing relationship is formed.
- Inadequate physician warning — the doctrine gives no protection where the warning itself fell short.
- Failure to update — new safety information not passed on defeats reliance on the rule.
Direct advertising is the most significant of these in practice. Where a manufacturer urges patients to ask their doctor about a product, some courts treat it as having voluntarily entered the patient decision, so a patient directed warning becomes necessary too. The fact that the prescriber independently knew of the risk does not resolve the point once that step has been taken.
A worked example
A patient in Los Angeles is prescribed a medicine and suffers a serious adverse effect. The product information provided to physicians mentioned the effect only in a general list without indicating that it could be severe or how often it occurred. The prescriber testifies that an accurate statement of the risk would have led her to choose an alternative. The warning was inadequate and causation is established.
Change the testimony. Suppose the prescriber says that the alternative was unsuitable for this patient and that she would have prescribed the same product even with a full warning. The inadequacy no longer caused the injury, and the warning claim fails even though the labelling was plainly deficient.
The doctrine in California and Los Angeles County in 2026
California recognises that the duty to warn for prescription products runs to the prescribing physician, and it has developed its own approach to prescription drug claims more broadly. California decisions have held that prescription drugs are not subject to ordinary design defect strict liability in the same way as other products, while confirming that failure to warn claims remain available where the manufacturer knew or should have known of a risk.
In Los Angeles County these claims typically combine expert evidence on the state of scientific knowledge at the relevant time with detailed testimony from the treating clinician, and federal preemption arguments about labelling frequently appear alongside the state law analysis.
- Warning duty preserved — failure to warn claims survive even where design claims are restricted.
- Knowledge standard — liability attaches to risks known or reasonably knowable at the time.
- Prescriber evidence — the treating clinician testimony usually decides causation.
- Advertising exposure — direct to consumer campaigns raise the question of patient directed warnings.
- Preemption — federal labelling requirements are commonly raised as a defence.
- Devices — prescription devices are analysed on the same intermediary logic.
For 2026, confirm the current California authority on prescription product warning duties, the scope of design claims and preemption directly with current authority, since these continue to develop.
Common mistakes to avoid
- Treating it as immunity — the doctrine redirects the warning duty and does not eliminate it.
- Skipping causation — a deficient warning is actionable only if a better one would have changed the decision.
- Ignoring direct advertising — marketing to patients can require patient directed warnings.
- Applying it to over the counter products — no intermediary exists, so the consumer must be warned.
- Overlooking mass immunisation — programmes without individual prescribing fall outside the rule.
- Assuming the original label suffices — warnings must be updated as safety information develops.
Frequently asked questions
Does the doctrine protect manufacturers completely?
No. It identifies who must be warned rather than removing the obligation. A claimant who shows that the information supplied to the prescriber was inadequate can still succeed, subject to proving that a better warning would have changed the outcome.
What is the direct to consumer exception?
Where a manufacturer advertises a prescription product directly to patients, some courts hold that it has entered the patient decision making process and must therefore warn the patient as well as the physician. The exception is the most frequently litigated route around the doctrine.
Does it apply to medical devices?
Yes, where the device is prescribed or implanted by a clinician who exercises independent judgement. The reasoning is identical, and the adequacy of the information given to that clinician is the central question.
Why does prescriber testimony matter so much?
Because causation turns on whether a different warning would have produced a different prescribing decision. If the treating clinician would have prescribed the product anyway, the inadequate warning did not cause the harm.
Are over the counter medicines covered?
No. Without a prescribing professional in the chain, the warning must reach the consumer directly, and ordinary warning defect analysis applies to the packaging and labelling.
Related guides
- Warning Defect
- Products Liability
- Design Defect
- Manufacturing Defect
- Strict Liability
- Proximate Cause
- Actual Cause
- Special Standards of Care
Next steps
Read this with warning defect for the general information defect framework, and then products liability for the wider set of theories a claimant can plead.
For primary sources, read California Civil Code section 1714 and the civil jury instructions published by the Judicial Council of California.